Research use only. Nothing on this page is medical advice, and no bioregulator is FDA-approved.
Bioregulators are peptides. They differ from regular peptide drugs in how they are claimed to act and in how much evidence backs them:
- Bioregulators come from Khavinson’s institute: chains of 2 to 4 amino acids, plus organ extracts (1)
- Regular peptide drugs: most bind receptors on the cell surface (2)
- Bioregulators: proposed to act on DNA inside the nucleus, an idea from the developers’ own group that hasn’t been shown in people (3)
Jump to the comparison, the two peptide groups, the evidence or the claims checked.
Bioregulators vs regular peptides, side by side
| Feature | Regular peptide drugs | Bioregulators |
|---|---|---|
| 1Size | 2 to 50 residues in the usual definition (2) | 2 to 7 residues, mostly 2 to 4 (1, 3) |
| 2Where they act | Over 90% of peptide drugs target receptors outside the cell (2) | Proposed to bind DNA and histones in the nucleus (3) |
| 3Getting into cells | Limited membrane permeability, though some peptides reach intracellular targets (2, 4) | The developers say short peptides enter cells and nuclei (3, 5) |
| 4How they are given | Mostly injected, because oral bioavailability is poor (2) | Sold as vials and capsules. We found no absorption data for the capsules |
| 5Approvals | Over 80 peptide drugs approved worldwide as of 2023 (2) | None by FDA. Russia registered Thymogen (6) |
| 6Biggest human evidence | Tirzepatide: phase 3 trials with over 7,700 participants (7) | A 266-person report from the developers’ institute (8) |
| 7Independent confirmation | Large-scale trials back the approved agents (7) | Reviews say rigorous trials are still needed. Epitalon has no Western randomized trial (7) |
Size isn’t the dividing line. The field’s usual definition of a peptide already covers 2 to 50 residues (2), so bioregulators sit at the short end of the same class.
Regular peptides are two groups
Most “regular peptide” talk mixes two groups. Approved drugs like tirzepatide have large trials behind them. Research peptides like BPC-157 and ipamorelin don’t, and reviews describe them with the same limits as bioregulators (7).
| Group | Examples | Status | Evidence |
|---|---|---|---|
| 1Approved peptide drugs | Tirzepatide, bremelanotide | FDA-approved for set uses | Large-scale trials. Tirzepatide’s phase 3 trials had over 7,700 participants (7) |
| 2Unapproved research peptides | BPC-157, TB-500, Semax, CJC-1295, ipamorelin | Not approved | Promising preclinical data, limited clinical data and no long-term safety data (7) |
| 3Bioregulators | Epitalon, Thymogen, Vilon, Pinealon | Not approved by FDA | The same gaps, plus most evidence coming from one research group |
Compare bioregulators with approved drugs, where the evidence gap is wide, and with research peptides, where the gaps look similar. Our best peptides by goal guide ranks the research peptides by human evidence.
Does the nuclear mechanism hold up?
The nuclear mechanism is the central claim. Khavinson’s group reports that peptides of 2 to 7 residues enter nuclei and bind histones H1, H2b, H3 and H4. It names EDR, AEDG, AEDL, KEDW, AEDR and KEDG as examples (3). A Russian review adds that these peptides are small and basic, which it says helps them cross membranes (5).
Both sources come from the tradition that makes the products, and the 2021 review is by the developers. We found no independent test of the mechanism in people. Treat it as a hypothesis built on modeling and cell work.
What does the evidence show for each?
| Question | Regular peptide drugs | Bioregulators |
|---|---|---|
| 1Randomized trials | Many for approved drugs. Tirzepatide has over 7,700 participants in phase 3 trials (7) | The main report followed 266 older people. The abstract doesn’t say how controls were chosen (8) |
| 2Long-term safety | Large-scale trial data for approved agents (7) | No long-term human safety data (7) |
| 3Dosing | Set by approved labels | Reviews call optimal dosing an open knowledge gap (7) |
| 4Safety signals | Tirzepatide: stomach side effects, with long-term heart outcomes still being studied (7) | Vilon raised mammary cancer in mice. Epitalon lengthened telomeres in breast cancer cells (9, 10) |
The gap is trial size and independence. The largest bioregulator human report followed 266 people and came from the group that developed the peptides, while approved peptides have trials of thousands.
Where the line blurs
Many bioregulators are ordinary peptides with a different label. Thymogen is a two-amino-acid bioregulator in Khavinson’s catalogue. A Western sponsor tested the same dipeptide as IM862 in a 202-patient phase III trial, and it failed: 23% responded on the drug against 21% on placebo (11).
Epitalon is a four-amino-acid peptide that sellers file under bioregulators, yet reviews describe it with the same terms as any investigational peptide: small studies and no long-term safety data (7).
Common claims, checked
| Claim | What the sources show |
|---|---|
| 1Bioregulators are legal supplements while peptides are banned | None is FDA-approved (12). HHS’s 28 October 2026 policy covers epitalon acetate, a bioregulator, for licensed pharmacies only, and excludes products sold as research chemicals or supplements (13) |
| 215 million people used them with no serious side effects | We found no source for that figure. Reviews say long-term human safety data are missing (7) |
| 3Short peptides survive the stomach, so capsules work | Poor oral bioavailability is a general weakness of peptides (2). We found no absorption data for bioregulator capsules |
| 4They extend lifespan by 20 to 40% | A developer review reports that for some preparations in rodents (14). Epitalon alone left mean lifespan unchanged in mice (15) |
| 5Decades of clinical trials prove they work | The institute reports clinical use over 6 to 12 years (14). Reviews say rigorous independent trials are still needed (7) |
| 6They are safer than injectable peptides | We found no head-to-head safety comparison, and Vilon raised mammary cancer in mice (9) |
How to judge a product from either class
- The exact name and sequence on the label and the lab report, for example AEDG for epitalon.
- Its approval status in your country. Sellers’ wording like “research use only” or “supplement” isn’t approval.
- A lot number on the report that matches your vial, with identity confirmed by mass spectrometry.
- Who ran the studies. Check whether anyone outside the developing group has repeated them.
Our guide to verifying a peptide COA explains each line of a report. For organ-by-organ detail, read the bioregulator peptides guide, and for single peptides see the Khavinson peptides list. For approved-class peptides, see best peptides by goal.
Where to buy bioregulator peptides
SwissChems sells the widest bioregulator range we found: 11 peptides as 20 mg vials (16). We don’t list doses or course schedules.
SwissChems bioregulator range
Eleven peptides · research use only
- Pinealon, Cortagen, Cardiogen, Livagen, Ovagen, Cartalax, Prostamax, Testagen, Bronchogen, Pancragen and Thymogen
- Free US shipping over $100, same-day US dispatch before 12 PM EST
- 30-day returns on unopened products
Bioregulators vs peptides FAQ
What is the difference between bioregulators and regular peptides?
Regular peptide drugs mostly bind receptors on the cell surface, and over 80 are approved worldwide. Bioregulators are 2 to 7 amino acid peptides proposed to act on DNA in the nucleus. That mechanism comes from the developers’ group, and no bioregulator is FDA-approved.
Are bioregulators peptides?
Yes. They are short peptides, mostly 2 to 4 amino acids, plus organ extracts. The claimed nuclear mechanism and the source of the evidence set them apart.
Are bioregulators safer than regular peptides?
No head-to-head comparison exists in the sources we found. Approved peptides have large-scale safety data. Bioregulators have no long-term human safety data, and Vilon raised mammary cancer in mice.
Do bioregulators work orally?
Oral absorption is a weak point for peptides in general, and we found no absorption data for bioregulator capsules.
Are bioregulators FDA approved or legal?
None is FDA-approved. An HHS policy from 28 October 2026 covers epitalon acetate only when a licensed pharmacy compounds it, and it excludes products sold as research chemicals or supplements.
What are examples of bioregulators?
Epitalon (AEDG), Thymogen (EW), Vilon (KE), Pinealon (EDR) and Vesugen (KED), plus organ extracts such as Thymalin and epithalamin.
What are cytogens and cytomaxes?
Sellers use cytogens for synthetic short peptides and cytomaxes for natural organ extracts.
Do bioregulators extend lifespan?
Not shown in people. A developer review reports 20 to 40% longer mean lifespan with some preparations in rodents, but epitalon alone left mean lifespan unchanged in mice.
How can you tell a real bioregulator product?
Match the lot number on your vial to a lab report that confirms the sequence by mass spectrometry, from a lab you can look up.
Sources
Show references (16)Hide references
- Khavinson V, et al. Peptide medicines: past, present, future. Klin Med (Mosk) 2020. Source
- Zheng B, et al. Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation. Int J Mol Sci 2025. Source
- Khavinson V, et al. Peptide regulation of gene expression: a systematic review. Molecules 2021. Source
- Apostolopoulos V, et al. A global review on short peptides: frontiers and perspectives. Molecules 2021. Source
- Boldyreva YV, et al. Mechanisms of biological activity of short peptides. Russian review 2024. Source
- Deigin V, et al. The first reciprocal activities of chiral peptide pharmaceuticals: Thymogen and Thymodepressin, as examples. Int J Mol Sci 2024. Source
- Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. Source
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. Source
- Anisimov VN, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2002. Source
- Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025;26:178. Source
- Noy A, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s sarcoma in a phase III trial. J Clin Oncol 2005. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content dated 22 April 2026). Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source
- Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology 2010. Source
- Anisimov VN, et al. Effect of epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003. Source
- SwissChems. Bioregulator product category (11 products, 20 mg vials). Source